Glipizide, a new and potent sulphonylurea derivative has been compared with tolbutamide in an open comparative study in terms of dosage, efficacy, toleration, incidence of primary and secondary failures and effect on the parameters of lipid metabolism.
Glipizide is a sulphonyleyelohexylurea with the following structural formula :
HsC~ Fig. 1 The chemistry, pharmacokinetics, and clinical results obtained with glipizide have been described in a series of recent papers [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11] .
Method
1. Prior to the onset of treatment with either trial drug both newly diagnosed cases and patients previously treated with oral antidiabetics were maintained on diet alone for a period of 3 to 7 days. The starting dose of glipizide was 2.5 mg and 5mg, respectively. Dosage adjustments were made every 3 to 7 days up to 20 rag/die (maximum 30 rag).
The daily dosage was either given as a single dose or, if this appeared to be necessary, as multiple doses. The dosage range of Tolbutamide was 500 mg to 4000 mg.
3. The following parameters were measured before treatment, weekly during the first month of treatment and then at monthly intervals: blood glucose levels (enzymatic) fasting and 1 and 2 h after a test meal (breakfast consisting of 27 g CH0=ll3 cMs); 24 h urinary glucose excretion; blood pressure and pulse in lying and standing position; and body weight.
4. Total cholesterol, free cholesterol, non-esterifled fatty acids, triglycerides, alkaline phosphatase, BUN, uric acid and the serum electrolytes Na+ and K+ were determined before treatment and then every 3 months.
Fundus examination and ECG were performed before treatment and will be repeated after 12 months therapy. The following limits were arbitrarily selected as reference values : Only three ranges (low, medium, high) are defined by these values, thus simplifying evaluation and not overstressing minor differences.
Criteria of
Fasting and 2 h values are lower, 1 h values higher compared with criterion Ch~ (see below), thus rendering the selected ranges more appropriate to the blood glucose values actually observed.
These values selected for the evaluation of results coincide with the values recommended for the diagnosis of diabetes [i2, 13]. The evaluation is based on the position of the arithmetic means of the blood glucose concentrations in this reference system (fasting value and i and 2 h after loading). The mean values were calculated from the blood glucose concentrations measured at the monthly assessment visits.
According to the distribution of these individual three mean values (fasting, 1 h, 2 h) for each patient under therapy, assessment is accomplished in the following way : half of the patients were 20 % or more overweight (8 of 16 in glipizide-group and 6 of t2 in tolbutamide-group).
Average weight changes from initial pretreatment values to values at last assessment visit were minimal (glipizide + 0.4%, range--4.0% to + 5.5%, tolbutamide + 0.7 %, range-3.1% to + 7.3 % of initial value). 6. Patient Selection: 40 patients with maturity-onset diabetes were allocated to one of the treatment groups (according to a randomization list) so that 20 patients were treated with glipizide and 20 patients with tolbutamide.
Glucosuria at monthly assessments: Glipizide
In the following the results obtained in 28 patients (16 glipizide, 12 tolbutamide) with a total of 84 monthly assessments (48 glipizide. 36 tolbutamide) are reported (see Tables 4, 5, 6) .
Summary of the assessments according to the criteria under point 5.
The mean values of all patients {with standard error) prior to treatment and during therapy (mean values of monthly assessments) with the trial drugs glipizide and tolbutamide are shown in Fig. 2 .
For ready orientation, the reference values (Ch 1. see method 5) are also shown in this figure.
There were no side effects, besides clinical signs of hypoglyeaemia in 4 patients on glipizide.
In patients No. 1, 5, 7, 15 a state with clinical signs of hypoglyeaemia (taehyeardia, increased perspiration, tremor) was observed approximately 5 h after lunch and about 9 h after intake of the daily dose of 2.5 mg glipizide. Blood glucose values taken at this stage continued with diet alone. This patient is not included in Tables 4 and 6 .
In 3 patients [5, 7, 20 ] the metabolic state improved under glipizide to such an extent that the patients could be transferred to diet alone after 3 months of treatment. Table 5 shows ~the values during [glipizide therapy only. excellent <110 rag/100 ml <150 mg/100 ml <130 rag/100 ml good < 130 mg/100 ml < 180 rag/100 ml < 150 rag/100 ml fair <150 rag/100 ml -<200 mg/100 ml <180 mg/100 ml poor -<220 rag/100 ml -<280 mg/100 ml <250 rag/100 ml negative > 220 rag/100 ml > 280 mg/100 ml > 250 mg/100 ml Beeause of the small number of patients and the short period of observation, only preliminary results can be presented. Sinee the blood glucose values recorded at the assessment visits constitute an essential, though not the only, criterion of evaluation and as there exists no generally accepted reference standard for the "chemical" evaluation [16] , the results were graded according to clinical criteria (C1) as well as two different "chemical" criteria (Chl, Ch~; see criteria of assessment, point 5, and Tables 4, 5, 6).
Taking into aecount that with the criterion Ch 1 a four-grade scale, and with the criteria C1 and Ch 2 a fivegrade scale is used for classification, the results ean be considered as more or less concordant. Where this is not the ease, as in patient No. 29 (Table 5) , the more flexible elinieal classification is better suited than the ealeulation of mean values of longer periods and the elassifieation according to rigid evaluation patterns.
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In the case of patient No. 29 frequent assessments and inquiries have shown that this patient had reduced the dose on her own. After the patient had observed the dosage recommended, the quality of control could be rated as moderate from the clinical point of view.
to the results of Emanueli et al. [9] . These authors stated that favourable control according to different criteria was possible in 76--83% of several hundred patients.
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When the criteria "excellent", "good" and "fair" (Table 4) are combined, it can be stated that in 80--90% of patients on glipizide and in 65--85% of patients on tolbutamide a reasonable degree of control could be achieved.
The results obtained with glipizide are comparable hour after load of patients on tolbutamide is somewhat higher than the corresponding value for glipizidepatients it can be stated that the blood-glucose lowering effect of glipizide is at least equal to that of tolbutamide. After completion of a 12 month treatment course in 40 patients (20 glipizide, 20 tolbutamide) further results, including also the parameters of lipid metabolism and other laboratory values, will be reported.
